This article was originally published in The Gray Sheet
BioEnterics subsidiary files PMA for its Lap-Band obesity treatment device Feb. 9 following completion of a 300-patient, eight-center clinical study with three-year follow-up. The device, which is comprised of a silicone elastomer band that can be inflated percutaneously with saline, can be placed laparoscopically around the upper part of the stomach, eliminating the need to cut, staple or bypass parts of the stomach or intestines, the firm claims
You may also be interested in...
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.
RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.